Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haloxon is an organophosphorus anthelmintic agent used in veterinary medicine, primarily for the treatment and control of gastrointestinal roundworm infections in cattle and other ruminants. It is effective against nematodes such as Haemonchus, Ostertagia, Trichostrongylus, Cooperia, Strongyloides papillosus, Bunostomum trigonocephalum, and Oesophagostomum venulosum. Haloxon's mechanism of action involves antagonism of cholinesterase enzymes (cholinesterase inhibitor), leading to paralysis and death of susceptible parasites. The drug is more active against adult worms than larval stages for some species. It should not be used concurrently with other cholinesterase-inhibiting agents due to risk of toxicity[1][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on haloxon.